Overview

A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to conduct an assessment of brain nociceptin/orphanin FQ peptide (NOP) receptor occupancy (RO) in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
BlackThorn Therapeutics, Inc.
Eli Lilly and Company
Treatments:
Nociceptin
Nocistatin